Uceris
Uceris contains budesonide, a synthetic corticosteroid with strong local anti-inflammatory activity but low systemic availability due to extensive first-pass metabolism. The extended-release tablets utilize multi-matrix (MMX) technology to delay release until reaching the colon, targeting the inflammation directly.
Dosage by Body Weight
For adults with active mild to moderate ulcerative colitis, the recommended oral dosage is one 9 mg tablet daily in the morning for up to 8 weeks. Tablets must be swallowed whole and not chewed, crushed, or broken. For Uceris rectal foam, the recommended dosage is 1 administration (2 mg) twice daily for 2 weeks, followed by 1 administration once daily for 4 weeks.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Uceris in pediatric patients have not been established.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Uceris in pediatric patients have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Uceris in pediatric patients have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Uceris in pediatric patients have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness of Uceris in pediatric patients have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Safety and effectiveness of Uceris in pediatric patients have not been established. |
| 5-7 kg | Not recommended | N/A | Safety and effectiveness of Uceris in pediatric patients have not been established. |
| 8-10 kg | Not recommended | N/A | Safety and effectiveness of Uceris in pediatric patients have not been established. |
| 11-15 kg | Not recommended | N/A | Safety and effectiveness of Uceris in pediatric patients have not been established. |
| 16-20 kg | Not recommended | N/A | Safety and effectiveness of Uceris in pediatric patients have not been established. |
Formulation
Purpose
Indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.
Generic Name
BudesonideScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.